Skip to main content
Erschienen in: Medical Microbiology and Immunology 6/2016

28.07.2016 | Original Investigation

HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy

verfasst von: Maximilian Donath, Timo Wolf, Martin Stürmer, Eva Herrmann, Markus Bickel, Pavel Khaykin, Siri Göpel, Peter Gute, Annette Haberl, Philipp de Leuw, Gundolf Schüttfort, Annemarie Berger, Christoph Stephan, for Frankfurt HIV Cohort Study

Erschienen in: Medical Microbiology and Immunology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

There are concerns about central nervous system (CNS)-replication of HIV-1 in patients on boosted protease inhibitors. Purpose of this study was to compare HIV-1 viral loads (VLs) from patients treated with only boosted dual protease inhibitor (bdPI), versus combination antiretroviral therapy (cART group), containing two nucleoside analogue reverse transcriptase inhibitors (NRTI) and a third partner. All patients from a large German HIV-treatment cohort with available medication, clinical and demographic data, including results from simultaneous HIV-1 viral load (VL) assessments in cerebrospinal fluid (CSF) and blood plasma, were retrospectively evaluated as controlled cross-sectional study. CSF had been obtained from patients with variable neurological symptoms during 2005–2014. Statistical analysis comprised nonparametric tests, regression and correlation techniques accounting for undetectable quantifications. Statistical analysis comprised nonparametric tests, regression and correlation techniques accounting for undetectable quantifications. Overall, 155 patients were evaluable (bdPI: 24; cART: 131). At time of CSF-collection, both groups were comparable in age, gender, CD4-cell counts, or primary HIV-transmission risks, though bdPI patients were clinically more advanced. The proportion of patients with undetectable HIV-1 (<50 copies/ml) in CSF was lower for bdPI group (25 vs 49.6 %; p = 0.026), but similar in plasma (46 vs 41 %). Median CSF-VL was higher in bdPI group (600 vs 50 copies/ml; p = 0.027) and similar in plasma. Mean VL CSF/plasma ratio was 342.91 for bdPI- and 54.48 for cART patients (p < 0.001). Pearson’s regression analysis revealed a trend for an elevated VL-ratio over time within bdPI group. HIV-1 replication was higher and more frequently detectable in CSF from bdPI patients, indicating a worse CNS penetration effectiveness of used boosted PI. Within bdPI group, measured CNS-viral replication was increasing over time, suggesting an over time impaired HIV-1 suppression in CSF.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stephan C, von Hentig N, Kourbeti I et al (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503–508CrossRefPubMed Stephan C, von Hentig N, Kourbeti I et al (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503–508CrossRefPubMed
2.
Zurück zum Zitat Staszewski S, Babacan E, Stephan C et al (2006) The LOPSAQ Study: 48-week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 58:1024–1030CrossRefPubMed Staszewski S, Babacan E, Stephan C et al (2006) The LOPSAQ Study: 48-week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 58:1024–1030CrossRefPubMed
3.
Zurück zum Zitat Stephan C, Bartha V, Herrmann E, von Hentig N, Khaykin P, Knecht G, Gute P, Brodt HR, Stürmer M, Berger A, Bickel M (2013) Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy. Med Microbiol Immunol 202:117–124CrossRefPubMed Stephan C, Bartha V, Herrmann E, von Hentig N, Khaykin P, Knecht G, Gute P, Brodt HR, Stürmer M, Berger A, Bickel M (2013) Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy. Med Microbiol Immunol 202:117–124CrossRefPubMed
4.
Zurück zum Zitat Yazdanpanah Y, Fagard C, Descamps D et al (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49:1441–1449CrossRefPubMed Yazdanpanah Y, Fagard C, Descamps D et al (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49:1441–1449CrossRefPubMed
5.
Zurück zum Zitat Imaz A, del Saz SV, Ribas MA et al (2009) Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 52:382–386CrossRefPubMed Imaz A, del Saz SV, Ribas MA et al (2009) Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 52:382–386CrossRefPubMed
6.
Zurück zum Zitat Arribas JR, Horban A, Gerstoft J et al (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24:223–230CrossRefPubMed Arribas JR, Horban A, Gerstoft J et al (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24:223–230CrossRefPubMed
7.
Zurück zum Zitat Katlama C, Valantin MA, Algarte-Genin M et al (2010) Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS 24:2365–2374PubMed Katlama C, Valantin MA, Algarte-Genin M et al (2010) Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS 24:2365–2374PubMed
8.
Zurück zum Zitat Kim RB, Fromm MF, Wandel C, Leake B et al (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294CrossRefPubMedPubMedCentral Kim RB, Fromm MF, Wandel C, Leake B et al (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Arribas JR, Clumeck N, Nelson M et al (2012) The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med 13:398–405CrossRefPubMed Arribas JR, Clumeck N, Nelson M et al (2012) The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med 13:398–405CrossRefPubMed
10.
Zurück zum Zitat Vernazza P, Daneel S, Schiffer V et al (2007) The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21:1309–1315CrossRefPubMed Vernazza P, Daneel S, Schiffer V et al (2007) The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21:1309–1315CrossRefPubMed
11.
12.
Zurück zum Zitat Stephan C, Hill A, Hadacek MB et al (2014) Performance of the Abbott RealTime HIV-1 assay versus the -Roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers. J Antimicrob Chemother 69:1708–1710CrossRefPubMed Stephan C, Hill A, Hadacek MB et al (2014) Performance of the Abbott RealTime HIV-1 assay versus the -Roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers. J Antimicrob Chemother 69:1708–1710CrossRefPubMed
13.
Zurück zum Zitat Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137–142PubMedPubMedCentral Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137–142PubMedPubMedCentral
14.
Zurück zum Zitat Akritas MG, Murphy SA, LaValley MP (1995) The Theil-Sen estimator with doubly censored data and applications to astronomy. J Am Stat Assoc 90:170–177CrossRef Akritas MG, Murphy SA, LaValley MP (1995) The Theil-Sen estimator with doubly censored data and applications to astronomy. J Am Stat Assoc 90:170–177CrossRef
15.
Zurück zum Zitat Fay MP, Shaw PA (2010) Exact and asymptotic weighted Logrank tests for interval censored data: the interval R package. J Stat Softw 36:1–34CrossRef Fay MP, Shaw PA (2010) Exact and asymptotic weighted Logrank tests for interval censored data: the interval R package. J Stat Softw 36:1–34CrossRef
16.
Zurück zum Zitat Marra CM, Zhao Y, Clifford DB et al (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366CrossRefPubMedPubMedCentral Marra CM, Zhao Y, Clifford DB et al (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Letendre S, Marquie-Beck J, Capparelli E et al (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70CrossRefPubMedPubMedCentral Letendre S, Marquie-Beck J, Capparelli E et al (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cysique LA, Waters EK, Brew BJ (2011) Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol 11:148CrossRefPubMedPubMedCentral Cysique LA, Waters EK, Brew BJ (2011) Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol 11:148CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Ferretti F, Gisslén M, Cinque P et al (2015) Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV/AIDS Rep 12:280–288CrossRefPubMed Ferretti F, Gisslén M, Cinque P et al (2015) Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV/AIDS Rep 12:280–288CrossRefPubMed
20.
Zurück zum Zitat Arribas J, Girard PM, Paton N et al (2014) Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. J Int AIDS Soc 17(4 Suppl 3):19788PubMedPubMedCentral Arribas J, Girard PM, Paton N et al (2014) Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. J Int AIDS Soc 17(4 Suppl 3):19788PubMedPubMedCentral
21.
Zurück zum Zitat Wolf T, Fuß B, Khaykin P, Berger A, Knecht G, Gute P et al (2014) Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis. Med Microbiol Immunol 203:409–414CrossRefPubMedPubMedCentral Wolf T, Fuß B, Khaykin P, Berger A, Knecht G, Gute P et al (2014) Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis. Med Microbiol Immunol 203:409–414CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Gisslén M, Fuchs D, Hagberg L et al (2012) Cerebrospinal fluid viral breakthrough in two HIV infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis 44:997–1000CrossRefPubMedPubMedCentral Gisslén M, Fuchs D, Hagberg L et al (2012) Cerebrospinal fluid viral breakthrough in two HIV infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis 44:997–1000CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Pasquet A, Ajana F, Melliez H et al (2012) Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS 26:1726–1728CrossRefPubMed Pasquet A, Ajana F, Melliez H et al (2012) Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS 26:1726–1728CrossRefPubMed
24.
Zurück zum Zitat Imaz A, Cayuela N, Niubó J et al (2014) Focal encephalitis related with viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir 30:984–987CrossRefPubMed Imaz A, Cayuela N, Niubó J et al (2014) Focal encephalitis related with viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir 30:984–987CrossRefPubMed
25.
Zurück zum Zitat Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A (2014) The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. J Int AIDS Soc 17(4 Suppl 3):19525PubMedPubMedCentral Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A (2014) The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. J Int AIDS Soc 17(4 Suppl 3):19525PubMedPubMedCentral
26.
Zurück zum Zitat PROTEA Trial Investigators. A clinical trial comparing the efficacy of darunavir/ritonavir monotherapy versus a triple combination therapy containing darunavir/ritonavir and 2 nucleoside/nucleotide reverse transcriptase inhibitors in patients with undetectable plasma HIV-1 RNA on current treatment (PROTEA). ClinicalTrials.gov-Identifier: NCT01448707; https://clinicaltrials.gov/ct2/show/NCT01448707. Accessed 18 Feb 2016 PROTEA Trial Investigators. A clinical trial comparing the efficacy of darunavir/ritonavir monotherapy versus a triple combination therapy containing darunavir/ritonavir and 2 nucleoside/nucleotide reverse transcriptase inhibitors in patients with undetectable plasma HIV-1 RNA on current treatment (PROTEA). ClinicalTrials.gov-Identifier: NCT01448707; https://​clinicaltrials.​gov/​ct2/​show/​NCT01448707. Accessed 18 Feb 2016
27.
Zurück zum Zitat Arribas J, Hill A (2010) Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression. HIV Ther 4:1758CrossRef Arribas J, Hill A (2010) Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression. HIV Ther 4:1758CrossRef
28.
Zurück zum Zitat Powderly W, Hill A, Moecklinghoff C (2014) Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials. HIV Clin Trials 15:79–86CrossRefPubMed Powderly W, Hill A, Moecklinghoff C (2014) Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials. HIV Clin Trials 15:79–86CrossRefPubMed
29.
Zurück zum Zitat Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, Decosterd LA, Cavassi-ni M, Yerly S, Vernazza PL, Swiss HIV Cohort Study (SHCS) (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24(15):2347–2354PubMed Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, Decosterd LA, Cavassi-ni M, Yerly S, Vernazza PL, Swiss HIV Cohort Study (SHCS) (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24(15):2347–2354PubMed
30.
Zurück zum Zitat Canestri A, Lescure FX, Jaureguiberry S et al (2010) Discordance between cerebral spinal fluid and plasma HIV repli-cation in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773–778CrossRefPubMed Canestri A, Lescure FX, Jaureguiberry S et al (2010) Discordance between cerebral spinal fluid and plasma HIV repli-cation in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773–778CrossRefPubMed
31.
Zurück zum Zitat Arribas J, Pulido F, Delgado R et al (2005) Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. J Acquir Immune Defic Syndr 40:280–287CrossRefPubMed Arribas J, Pulido F, Delgado R et al (2005) Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. J Acquir Immune Defic Syndr 40:280–287CrossRefPubMed
32.
Zurück zum Zitat Nunes E, Santini de Olveira M, Mercon M et al (2009) Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomised, controlled, open-label pilot trial (KalMo Study). HIV Clin Trials 10:368–374CrossRefPubMed Nunes E, Santini de Olveira M, Mercon M et al (2009) Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomised, controlled, open-label pilot trial (KalMo Study). HIV Clin Trials 10:368–374CrossRefPubMed
33.
Zurück zum Zitat Bernardino J, Pulido F, Martinez E et al (2013) Switching to lopinavir-ritonavir with or without abacavir and lamivudine in lipoatrophic patients treated with zidovudine/lamivudine/abacavir. J Antimicrob Chemother 11:1373–1381CrossRef Bernardino J, Pulido F, Martinez E et al (2013) Switching to lopinavir-ritonavir with or without abacavir and lamivudine in lipoatrophic patients treated with zidovudine/lamivudine/abacavir. J Antimicrob Chemother 11:1373–1381CrossRef
34.
Zurück zum Zitat Meynard J, Bouteloup V, Landman R et al (2010) Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 65:2436–2444CrossRefPubMed Meynard J, Bouteloup V, Landman R et al (2010) Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 65:2436–2444CrossRefPubMed
35.
Zurück zum Zitat Reinheimer C, Wesner A, Keppler OT, Doerr HW, Herrmann E, Stürmer M et al. (2016) Prevalence of K65R in Patients Treated with Tenofovir Disoproxil Fumarate: Recommendations Based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD). Med Microbiol Immunol. 2016 Jan 8. [Epub ahead of print]. PMID: 26746222 Reinheimer C, Wesner A, Keppler OT, Doerr HW, Herrmann E, Stürmer M et al. (2016) Prevalence of K65R in Patients Treated with Tenofovir Disoproxil Fumarate: Recommendations Based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD). Med Microbiol Immunol. 2016 Jan 8. [Epub ahead of print]. PMID: 26746222
36.
Zurück zum Zitat Eggers C, Hertogs K, Stürenburg HJ, van Lunzen J, Stellbrink HJ et al (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17(13):1897–1906CrossRefPubMed Eggers C, Hertogs K, Stürenburg HJ, van Lunzen J, Stellbrink HJ et al (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17(13):1897–1906CrossRefPubMed
Metadaten
Titel
HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy
verfasst von
Maximilian Donath
Timo Wolf
Martin Stürmer
Eva Herrmann
Markus Bickel
Pavel Khaykin
Siri Göpel
Peter Gute
Annette Haberl
Philipp de Leuw
Gundolf Schüttfort
Annemarie Berger
Christoph Stephan
for Frankfurt HIV Cohort Study
Publikationsdatum
28.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Medical Microbiology and Immunology / Ausgabe 6/2016
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-016-0469-7

Weitere Artikel der Ausgabe 6/2016

Medical Microbiology and Immunology 6/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.